L autokinase activity in K562 chronic myelogenous leukemia. Anticancer Drugs 1994;5:213-222. ten. Brunstein CG, McGlave PB. The biology and remedy of chronic myelogenous leukemia. Oncology 2001;15:23-31. 11. Hughes TP, Kaeda J, Branford S. Frequency of major molecular responses to imatinib or alpha-interferon plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2004;349:1423-1432. 12. Deininger MWN, O’Brien SG, Ford JM. Sensible management of patients with chronic myeloid leukemia getting imatinib. J Clin Oncol 2003;21:1-11. 13. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F Schiffer , G, Gambacorti-Passerini C, Niederwieser D. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-652. 14. Talpaz M, Silver RT, Druker BJ. Imatinib induces sturdy hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase two study. Blood 2002;99:1928-1937. 15. Druker BJ, Sawyers CL, Kantarjian H. Activity of a specific inhibitor on the BCR-ABL tyrosine kinase inside the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia together with the Philadelphia chromosome. N Engl J Med 2001;344:1038-1042. 16. Druker BJ, Guilhot F O’Brien S, Larson RA, on behalf on the , IRIS. Long-term positive aspects of imatinib (IM) for individuals newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP): the 5-year update from the IRIS study. J Clin Oncol 2006;24:338.17. Breccia M, Stefanizzi C, Cannella L, Latagliata R, Frustaci AM, Carmosino I, Santopietro M, Alimena G. Variations in hematological and non-hematological toxicity through treatment with imatinib in sufferers with early and late chronic phase chronic myeloid leukemia. Leuk Lymphoma 2008;49:2328-2832. 18. Hensley ML, Ford JM. Imatinib treatment: particular concerns associated with safety, fertility, and pregnancy. Semin Hematol 2003;40:21-25. 19. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. Efficacy and safety of a precise inhibitor from the bcr-abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037. 20. Esmaeli B, Prieto VG, Butler CE, Kim SK, Ahmadi MA, Kantarjian HM, Talpaz M.Osanetant web Extreme periorbital edema secondary to STI571 (Gleevec).IKB alpha Antibody MedChemExpress Cancer 2002;95:881-887.PMID:23376608 21. Reichard KK, Larson RS, Rabinowitz I. Chronic myeloid leukemia. In: Green JP, Foerster J, Rodgers GM, Paraskevas F Glader B, Arber DA, Indicates RT Jr, editors. Wintrobe’s , Clinical Hematology. 12th ed. Philadelphia: Lippincott Williams and Wilkins; 2009. pp. 2006-2030. 22. Cross TJ, Bagot C, Portmann B, Wendon J, Gillett D. Imatinib mesylate as a reason for acute liver failure. Am J Hematol 2006;83:189-192. 23. Etienne G, Cony-Makhoul P, Mahon FX. Imatinib mesylate and gray hair. N Engl J Med 2002;347:446. 24. Legros L, Cassuto JP, Ortonne JP. Imatinib mesilate (Glivec): a systemic depigmenting agent for in depth vitiligo Br J Dermatol 2005;153:691-692. 25. Silva de Castro C, Machado do Nascimento L, Walker G, Werneck RI, Nogoceke E, Mira M. Genetic variants from the DDR1 gene are related with vitiligo in two independent Brazilian population samples. J Invest Dermatol 2010;130:1813-1818. 26. Atallah E, Durand JB, Kantarjian H, Cortes J. Congestive heart failure is actually a rare event in individuals getting imatinib therapy. Blood 2007;110:1233-1237.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 288, NO. 19, pp. 1329.
Sodium channel sodium-channel.com
Just another WordPress site
